JOHN VALLES: Open Payments
NPI 1972545994 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,958 in 85 payments from 9 companies in 2025. Trend: 2023 $1,536 · 2024 $1,735 · 2025 $1,958
Food & beverage: $1,958
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $448 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $352 |
| Janssen Pharmaceuticals, Inc | 8 | $279 |
| Otsuka America Pharmaceutical, Inc. | 11 | $222 |
| E.R. Squibb & Sons, L.L.C. | 10 | $218 |
| Neurocrine BioSciences, Inc. | 10 | $177 |
| Teva Pharmaceuticals USA, Inc. | 11 | $166 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| ABBVIE INC. | 1 | $26 |
Products named: CAPLYTA, ARISTADA, INVEGA SUSTENNA, COBENFY, REXULTI, INGREZZA, LYBALVI, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
